Status:
COMPLETED
A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Renal Cell Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This 2-arm study will evaluate the efficacy and safety of Avastin versus placebo in combination with Roferon as first-line treatment in participants with metastatic renal cell cancer (clear cell type)...
Eligibility Criteria
Inclusion
- metastatic renal cell cancer (clear cell type);
- nephrectomy;
- absence of proteinuria.
Exclusion
- prior systemic treatment for metastatic renal cell cancer;
- major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to study treatment start;
- presence of brain metastases or spinal cord compression;
- ongoing need for full dose anticoagulants;
- uncontrolled hypertension;
- clinically significant cardiovascular disease.
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
649 Patients enrolled
Trial Details
Trial ID
NCT00738530
Start Date
June 1 2004
End Date
September 1 2008
Last Update
June 23 2016
Active Locations (104)
Enter a location and click search to find clinical trials sorted by distance.
1
Adelaide, Australia, 5011
2
Adelaide, Australia, 5041
3
Brisbane, Australia, 4006
4
Canberra, Australia, 2606